Search hospitals > Ohio > Cincinnati
Oncology Hematology Care, Inc.
Claim this profileCincinnati, Ohio 45242
Global Leader in Lung Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lymphoma
297 reported clinical trials
11 medical researchers
Summary
Oncology Hematology Care, Inc. is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lymphoma and other specialties. Oncology Hematology Care, Inc. is involved with conducting 297 clinical trials across 254 conditions. There are 11 research doctors associated with this hospital, such as Howard M. Gross, Kruti Patel, David M Waterhouse, and Patrick Ward.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage I
2Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Howard M. GrossDayton Physician LLC-Miami Valley Hospital North4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
128 reported clinical trials
194 drugs studied
Kruti PatelGreater Baltimore Medical Center4 years of reported clinical research
Studies Leukemia
Studies Myeloid Leukemia
9 reported clinical trials
18 drugs studied
David M WaterhouseOncology Hematology Care3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
7 reported clinical trials
15 drugs studied
Patrick WardOncology Hematology Care7 years of reported clinical research
Studies Breast Cancer
Studies Cancer
5 reported clinical trials
13 drugs studied
Clinical Trials running at Oncology Hematology Care, Inc.
Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Non-Hodgkin's Lymphoma
Lymphoma
Cancer
Multiple Myeloma
Squamous Cell Carcinoma
Laryngeal Cancer
Leukemia
Sigvotatug Vedotin vs Docetaxel
for Lung Cancer
This trial is testing a new drug, sigvotatug vedotin, against a standard drug, docetaxel, in patients with advanced lung cancer. The goal is to see if the new drug works better and to understand its side effects. Docetaxel (Taxotere) is a well-established chemotherapy agent used in the treatment of advanced non-small cell lung cancer (NSCLC), often after failure of first-line treatments.
Recruiting2 awards Phase 35 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Brentuximab Vedotin + Pembrolizumab
for Advanced Cancers
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Recruiting1 award Phase 27 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Oncology Hematology Care, Inc.?
Oncology Hematology Care, Inc. is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lymphoma and other specialties. Oncology Hematology Care, Inc. is involved with conducting 297 clinical trials across 254 conditions. There are 11 research doctors associated with this hospital, such as Howard M. Gross, Kruti Patel, David M Waterhouse, and Patrick Ward.